Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.
Ontology highlight
ABSTRACT: Oncogene-addicted cancers are predominantly driven by specific oncogenic pathways and display initial exquisite sensitivity to designer therapies, but eventually become refractory to treatments. Clear understanding of lung tumorigenic mechanisms is essential for improved therapies. Methods: Lysosomes were analyzed in EGFR-WT and mutant cells and corresponding patient samples using immunofluorescence or immunohistochemistry and immunoblotting. Microtubule organization and dynamics were studied using immunofluorescence analyses. Also, we have validated our findings in a transgenic mouse model that contain EGFR-TKI resistant mutations. Results: We herein describe a novel mechanism that a mutated kinase disrupts the microtubule organization and results in a defective endosomal/ly
SUBMITTER: Chin TM
PROVIDER: S-EPMC7052910 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA